Bausch + Lomb advances dry-eye Phase 3 candidate, BL1332 Phase 1b
Bausch + Lomb moves its dual-action dry-eye candidate into Phase 3 after mixed Phase 2 results and reports positive Phase 1b ocular-surface pain data for BL1332.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.